Consolidation Therapy in Newly Diagnosed PCNSL Remains Undefined
Researchers sought to determine whether myeloablative consolidation after induction therapy would improve PFS in patients with newly diagnosed primary central nervous system lymphoma.
Diagnosis & Disease Information
Ibrutinib, Venetoclax Combination Shows Promise in Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Researchers sought to determine whether combination ibrutinib and venetoclax would have durable responses in patients with CLL and SLL.
Model May Identify Non-ETP T-ALL Patients at High Risk of Poor Response to Treatment
The model appears to predict minimal residual disease status.
Phase 3 Trial Evaluating Venetoclax, Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes
Researchers are conducting a randomized phase 3 trial evaluating the safety and efficacy of venetoclax with azacitidine among patients with previously untreated, higher-risk MDS.
Phase 4 Feasibility Trial Is Evaluating At-Home Treatment of MRD-Positive BCP-ALL
Researchers are running a phase 4 feasibility trial to determine the safety and effectiveness of at-home blinatumomab treatment in patients with MRD-positive B cell precursor ALL.
Adding Ixazomib to Dexamethasone Does Not Improve PFS Compared to Pomalidomide in Multiple Myeloma
Researchers sought to determine whether doublet therapy with dexamethasone and ixazomib would improve survival in patients with multiple myeloma compared with pomalidomide.
CAR-T Cell Therapy Shows Promise in Pretreated Patients With Multiple Myeloma
Researchers sought to determine whether cilta-cel would have clinical activity in patients with previously treated multiple myeloma.
Patients With Acute Myeloid Leukemia May Have Suboptimal Outcomes Because of Fears of Treatment Side Effects
Researchers sought to determine whether patients with AML were being undertreated due to patient fear about side effects to treatment.
Enasidenib With Azacitidine May Improve Survival in Patients With IDH2-Mutated Myelodysplastic Syndrome
Researchers sought to determine whether enasidenib combined with azacitidine may increase survival in patients with IDH2-mutated myelodysplastic syndrome.
Anti-CLL1 CAR T Cells Produce Responses in Pediatric Acute Myeloid Leukemia
Eight patients had a complete response within 1 month of infusion.
- Loading...
Loading...
Next post in ASCO 2021
Loading... 
Loading...